Open Access

Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines

  • Authors:
    • Hui‑Li Wang
    • Yan‑Chun Liu
    • Ming‑Peng Long
    • Chuan Zheng
    • Jia‑Hui Yang
  • View Affiliations

  • Published online on: July 22, 2019     https://doi.org/10.3892/ol.2019.10643
  • Pages: 2977-2984
  • Copyright : © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Treatment strategies involving tyrosine kinase inhibitors (TKIs) for patients with non‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations have advanced significantly; however, challenges still remain regarding the development of resistance. It has been reported that receptor tyrosine kinase‑like orphan receptor 1 (ROR1) acts as a hepatocyte growth factor receptor (MET) and c‑Src substrate, and that the extracellular domain of ROR1 is associated with EGFR to sustain EGFR‑ERBB3‑PI3K signaling. Our previous study reported that blocking ROR1 significantly decreased the activity of key signal molecules in the AKT/mammalian target of rapamycin (mTOR) signaling pathway, which was associated with a significant increase of apoptosis and significant decrease of proliferation of lung adenocarcinoma cells. The present study hypothesized that inhibiting ROR1 could potentially prevent erlotinib resistance in NSCLC cell lines. Investigations were performed with two erlotinib‑resistant cell lines XLA‑07 and NCI‑H1975, and an erlotinib‑acquired‑resistant cell line PC‑9erlo, which was developed from its parental cell line PC‑9. It was identified that the inhibition of ROR1 via small interfering RNA treatment significantly improved the anti‑proliferation and apoptosis‑inducing roles of erlotinib in TKI‑resistant tumor cells. This was in accordance with the activity of key molecules of the AKT/mTOR signaling pathway, including glycogen synthase kinase‑3α/β (GSK‑3α/β), phosphatase and tensin homolog (PTEN), AKT, mTOR and ribosomal protein S6 kinase β‑1 (p70S6K). The current data suggest that targeting ROR1 is a potential novel treatment strategy for patients with ROR1‑positive NSCLC, particularly those with acquired resistance to EGFR‑TKI.
View Figures
View References

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, H., Liu, Y., Long, M., Zheng, C., & Yang, J. (2019). Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines. Oncology Letters, 18, 2977-2984. https://doi.org/10.3892/ol.2019.10643
MLA
Wang, H., Liu, Y., Long, M., Zheng, C., Yang, J."Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines". Oncology Letters 18.3 (2019): 2977-2984.
Chicago
Wang, H., Liu, Y., Long, M., Zheng, C., Yang, J."Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines". Oncology Letters 18, no. 3 (2019): 2977-2984. https://doi.org/10.3892/ol.2019.10643